The Philadelphia translocation is associated with a poor prognumber of leukemic cells remaining at the end of induction nosis in adults and children with acute lymphoblastic leukemia, provides a good approximation of the degree of drug resisteven though the majority of patients achieve remission. To test ance in vivo. adults.
Introduction
Patients were eligible for this study if: (1) they had B lineage It is well known that the presence of the Philadelphia translo-ALL; (2) their leukemia could be quantified by the techniques cation (t(9;22)(q34;q11)) markedly worsens the prognosis of described below; (3) they achieved morphological remission children and adults with acute lymphoblastic leukemia after induction treatment, and (4) there was enough material (ALL). 1, 2 Philadelphia-positive (Ph+ve) patients achieve available for study. Patients were excluded if their cytogenetic remission less frequently or take longer to do so, and, even if testing was unsuccessful, or revealed a translocation other they achieve remission, most will relapse. The most obvious than the t(9;22): 23 otherwise eligible patients had no cytoexplanation is that the 9;22 translocation directly increases genetic information available, mainly due to technical probdrug resistance even in patients who achieve remission. There lems; another 13 patients were not studied because they had is some evidence supporting this, as in several in vitro studies a translocation other than t(9;22) associated with higher on chronic myelogenous leukemia the presence of the bcr-abl relapse risk, eg t(1;19), t(4;11) or t(8;14). The 20 adult patients fusion gene prevented apoptosis following drug exposure. [3] [4] [5] had been treated between 1984 and 1994 with the 7801-A However, other explanations of the poor outcome in Ph+ve protocol which involved a 5-week induction therapy of vincri-ALL are possible. For example, the 9;22 translocation might stine, prednisolone, daunorubicin, cytosine arabinoside, and increase genetic instability and drug resistance could be a asparaginase. The clinical features of most have been consequence of one or more secondary mutations. Alternadescribed. 13 The Philadelphia-negative adult patients (10 tively the 9;22 translocation might lead to a poor outcome by male, three female) had at diagnosis a median white cell mechanisms entirely unrelated to drug resistance. count 13 × 10 9 /l (range 3-57 × 10 9 /l) and median age of 21 In vivo drug resistance can be inferred from the rate of (range . Clinical data for Philadelphia-positive adults decline of leukemic cell number during treatment. However, are shown in Table 1 . Three patients, including two with the since the number of leukemic cells in the body at diagnosis t(9;22), had white cell counts above 50 × 10 9 /l ( ; P = 0.0008). For adults, the MRD levels at the end of induction in Ph+ve patients were not significantly ; P = 0.18; one-tailed). Table 1 . Twelve patients, including three with the t(9;22), had white cell counts above 50 × 10 9 /l. This work was approved by the Flinders Medical Centre Committee on Clinical Investigation.
Tissue samples
Bone marrow was aspirated at diagnosis and at the end of induction treatment, and was usually available as fixed, stained bone marrow smears, although unfixed smears or frozen marrow were sometimes used.
Quantification of minimal residual disease
This was performed as previously described.
11-14 Briefly, DNA was extracted by phenol-chloroform extraction. The rearranged immunoglobulin heavy chain gene, which acts as a marker for the leukemic clone, was amplified from the bone marrow at diagnosis, and sequenced. PCR primers were designed to the complementary determining region (CDR)3 and occasionally CDR2 regions and tested for specificity and sensitivity by ensuring that large amounts of amplified product of the correct size were obtained from one or a few molecules of the target DNA, and by demonstrating that no signal was obtained from 1 g DNA from peripheral blood obtained from a healthy volunteer. Quantification was performed by using limiting dilution analysis. For leukemic genomes we used a nested PCR either with consensus primers or occasionally with one patient-specific primer and one consensus primer in the first round, followed by one or two patient-specific primers in the second round. For total amplifiable genomes we used primers for the N-ras gene in a one-round PCR. MRD levels were expressed as the proportion of nucleated cells which belong to the leukemic clone.
Sequences of the rearranged immunoglobulin heavy chain can be obtained from the authors.
MRD was not detected in the other 35 patients, in part at from in vitro experiments which indicate that the bcr-abl translocation inhibits drug-induced apoptosis. [3] [4] [5] If the bcr-abl least because too little DNA was available. However, it was possible to estimate an upper limit for the level of residual translocation were to lead directly to drug resistance then it would be predicted that the degree of drug resistance would leukemia from the number of genomes studied (Figure 1, open  circles) . If, conservatively, it is assumed that the level of MRD be relatively homogenous, both in the population of patients with the translocation and in the population of leukemic cells was actually equivalent to this upper limit, inclusion of these patients still indicated that Ph+ve children had significantly within any one patient. However, an indirect effect is also possible if the translocation increases genetic instability. If a higher levels than Ph−ve children (P = 0.0008, one-tailed) whereas Ph+ve adults did not have significantly higher levels second genetic change were to be responsible for development of drug resistance, and if it were to occur at a higher than Ph−ve adults (P = 0.37, one-tailed).
Sufficient DNA was available for all patients to show frequency as the result of the bcr-abl translocation, then the second event could occur early in the course of the disease whether a patient had MRD Ͼ10 −3 (see Table 2 ). For children, significantly more Ph+ve patients had MRD Ͼ10 −3 than Ph−ve in the majority of Ph+ve patients but later in the majority of Ph−ve patients. Consequently, Ph+ve patients would tend to patients (Fishers exact probability test, P = 0.0007, one-tailed). For adults, the difference was not significant (P = 0.642, be relatively drug resistant at diagnosis whereas Ph−ve patients would tend to be relatively drug sensitive at diagnosis, one-tailed).
Three of the seven Ph+ve children (43%) had at diagnosis but would develop drug resistance subsequently. Our data provide some support for this latter hypothesis, as a few of a white cell count above 50 × 10 9 /l, compared to nine of the 54 Ph−ve children (17%). It might be argued that a higher our patients appeared at diagnosis to be still sensitive to therapy. Other data also indicate that the (9;22) translocation number of leukemic cells in Ph+ve patients, rather than any increase in resistance to treatment, led to high levels of leads to secondary mutations, at least in chronic myeloid leukemia, as p53 mutations are commonly observed late in the residual leukemia at the end of induction. To test this possibility, the three Ph+ve and nine Ph−ve children with high disease 15, 16 and at blast crisis, which probably has a genetic basis, develops in most patients. white cell counts were excluded, and the median MRD levels again compared. Ph+ve children still had a higher MRD level
The results in adults were different from those observed in children. We have previously reported that at the end of than did Ph−ve patients (patients with MRD detected: P = 0.018; all patients: P = 0.011, one-tailed). A similar result was induction, the levels of MRD in Ph−ve adults were increased compared to those in Ph−ve children. 13 This is also seen in also obtained for the 12 patients with a high WCC (all patients: Mann-Whitney U test, P = 0.001). This suggests that Figure 1 which shows that in adults there was no clear evidence of a further increase associated with presence of the a higher number of leukemic cells in Ph+ve child patients at diagnosis did not account for the higher level of MRD after 9;22 translocation. These observations suggest that in vivo drug resistance is already present in most adults with Ph−ve induction.
To study the effect of age alone, the levels of MRD in adults ALL and is increased little if at all by the translocation. There are at least three possible explanations for this difference and children were compared for patients in whom MRD was detected. For Ph+ve patients there was no significant differbetween adults and children. Firstly, cells in adults may differ from those in children in pathways, such as drug metabolism, ence between adults and children (P = 0.27, two-tailed), whereas for Ph−ve patients, adults had a significantly higher which are related to drug resistance. 17 Secondly, the leukemia in adults may differ biologically from that in children, eg in MRD level than children (P = 0.0097, one-tailed). Inclusion of the patients in whom MRD was not detected did not alter the prevalence of various subtypes or of mutations associated with drug resistance. An example of the latter is the t(12;21) the conclusions significantly (Ph+ve: P ϭ 0.24; Ph−ve patients: P = 0.004, one-tailed).
which occurs commonly in childhood but rarely in adult ALL 18, 19 and which is associated with an excellent response to treatment. Thirdly, children and adults may have different forms of the t(9;22) and these forms may lead to different levDiscussion els of drug resistance. Most children, but only about a third of adults, produce a p190 bcr-abl fusion protein, and the rest Children with Ph+ve ALL have significantly higher levels of MRD at the end of induction than do children with Ph−ve produce a p210 bcr-abl fusion protein. The two forms may have different biological activities, 20 and in transgenic animals ALL. This difference is not due to a higher overall number of leukemic cells at diagnosis in the Ph+ve children and we there is evidence that they affect the course of disease differently. 21 Finally, if the (9;22) translocation were to have only conclude that in children the (9;22) translocation increases drug resistance in vivo. This increase may be a direct effect a small effect in adults, then such an effect could have been missed in our study. The number of patients studied was small of the translocation, and supporting evidence for this comes and, as cytogenetics occasionally fails to detect the translocation, 19 occasional patients with the translocation could have eradicating the last clonogenic leukemic cell; a large leukemic population during treatment increases the probability of
